Abbvie Inc.

Maria Harris

Jijie Gu

Chung-Ming Hsieh

Tariq Ghayur

Lorenzo Benatuil

Yuliya Kutskova

Susan Elizabeth Morgan-Lappe

Erwin R Boghaert

Yingchun Li

Jonathan A Hickson

Zhihong Liu

Carrie Goodreau

Sonal Saluja

Charles W Hutchins

Jochen G Salfeld

Anwar Murtaza

Edit Tarcsa

Junjian Liu

Peter C Isakson

Michael McPherson

Jjijie Gu

Rong-rong Zhu

Jianwei Shen

Eileen Belanger

William B Stine

Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.

Therapeutic DLL4 binding proteins

Engineered multivalent and multispecific binding proteins that bind IL-1&#x3b2; and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.

Dual specific binding proteins directed against IL-1 and/or IL-17

Dual specific binding proteins directed against IL-1&#x3b2; and/or IL-17

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Dual variable domain immunoglobulins and uses thereof

The present invention encompasses prostaglandin E(PGE) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin Eand neutralize prostaglandin Eactivity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin Eand for inhibiting prostaglandin Eactivity, e.g., in a human subject suffering from a disorder in which prostaglandin Eactivity is detrimental.

Prostaglandin E2 binding proteins and uses thereof

Growing community of inventors

Shrewsbury, MA, United States of America

Maria Harris